Palemo控股
2778
Spancrete
5277
Renascience
4889
Oncolys BioPharma
4588
北川精機
6327
(FY)2024/03/31 | (Q4)2024/03/31 | (Q3)2023/12/31 | (Q2)2023/09/30 | (Q1)2023/06/30 | (FY)2023/03/31 | (Q4)2023/03/31 | (Q3)2022/12/31 | (Q2)2022/09/30 | (Q1)2022/06/30 | |
---|---|---|---|---|---|---|---|---|---|---|
營業總收入 | 11.92%52.43億 | 20.30%15.13億 | 7.75%13.48億 | 1.52%12.02億 | 18.95%11.8億 | 33.79%46.84億 | 21.01%12.58億 | 32.66%12.51億 | 20.73%11.84億 | 84.25%9.92億 |
主營業務成本 | 11.35%40.74億 | 11.42%11.12億 | 5.55%10.43億 | 13.45%9.66億 | 16.09%9.53億 | 34.68%36.58億 | 19.80%9.98億 | 39.33%9.88億 | 9.73%8.51億 | 106.17%8.21億 |
毛利 | 13.94%11.69億 | 54.40%4.02億 | 16.06%3.05億 | -29.01%2.36億 | 32.69%2.27億 | 30.70%10.26億 | 25.88%2.6億 | 12.39%2.62億 | 62.40%3.33億 | 21.99%1.71億 |
營業費用 | 4.96%8.71億 | 6.36%2.2億 | 14.26%2.36億 | 4.37%2.27億 | -5.54%1.88億 | 18.94%8.3億 | 2.60%2.07億 | 7.47%2.07億 | 28.53%2.18億 | 47.75%1.99億 |
營業利潤 | 51.90%2.98億 | 240.49%1.82億 | 22.77%6,840.1萬 | -92.25%891.4萬 | 241.28%3,917.4萬 | 124.61%1.96億 | 940.53%5,336.9萬 | 35.39%5,571.4萬 | 224.23%1.15億 | -589.18%-2,772.7萬 |
營業外利息收入與支出淨額 | -70.59%-6,116.7萬 | -59.03%-1,664.9萬 | -94.02%-1,696.3萬 | -46.45%-1,289.9萬 | -87.01%-1,465.6萬 | -16.03%-3,585.7萬 | -48.98%-1,046.9萬 | 8.96%-874.3萬 | 18.25%-880.8萬 | -123.91%-783.7萬 |
營業外利息收入 | 311.18%691.2萬 | 113.36%244.3萬 | 333.16%167.2萬 | 1,569.00%166.9萬 | 2,156.00%112.8萬 | 312.01%168.1萬 | 1,022.55%114.5萬 | 289.90%38.6萬 | 128.33%10萬 | -91.07%5萬 |
營業外利息支出 | 81.36%6,807.9萬 | 64.39%1,909.2萬 | 104.13%1,863.5萬 | 63.54%1,456.8萬 | 100.13%1,578.4萬 | 19.88%3,753.8萬 | 62.91%1,161.4萬 | -5.91%912.9萬 | -14.52%890.8萬 | 94.26%788.7萬 |
投資淨收益 | 42.59%5,574.3萬 | 56.57%2,679.6萬 | -486.05%-840.4萬 | 41.14%1,346.3萬 | 72.17%2,388.8萬 | 14.99%3,909.4萬 | -4.60%1,711.4萬 | -108.69%-143.4萬 | 1,603.39%953.9萬 | 1,476.49%1,387.5萬 |
被指定為現金流套期的金融工具損益 | ||||||||||
終止確認可供出售金融資產損益 | ||||||||||
聯營企業及其他參股權益產生的收益 | ||||||||||
特殊收入(費用) | -123.93%-855.8萬 | 123.01%96.4萬 | -101.84%-80.2萬 | -31,233.33%-840.6萬 | 91.33%-31.4萬 | 266.62%3,576.3萬 | -419,100.00%-419萬 | 303.63%4,354.7萬 | 250.00%2.7萬 | -5,740.32%-362.1萬 |
減:其他特殊費用 | 123.93%855.8萬 | -123.01%-96.4萬 | 101.84%80.2萬 | 31,233.33%840.6萬 | -91.33%31.4萬 | -266.62%-3,576.3萬 | 419,100.00%419萬 | -303.63%-4,354.7萬 | -250.00%-2.7萬 | 5,740.32%362.1萬 |
其他營業外收入(費用) | -80.76%797.3萬 | -97.39%18.9萬 | -39.68%269.8萬 | 269.27%277.6萬 | -92.63%231萬 | -36.77%4,143.1萬 | -87.49%723.4萬 | -10.75%447.3萬 | -698.54%-164萬 | 1,190.17%3,136.4萬 |
稅前利潤 | 5.58%2.92億 | 206.09%1.93億 | -51.97%4,493.2萬 | -96.63%384.6萬 | 732.56%5,040.3萬 | 105.67%2.77億 | -14.61%6,305.9萬 | 195.30%9,355.6萬 | 347.37%1.14億 | 71.55%605.4萬 |
所得稅 | 10.52%9,418.3萬 | 6,351.00%4,515.7萬 | -66.97%1,537萬 | 40.95%2,163.4萬 | -46.89%1,202.2萬 | 84.78%8,522萬 | -96.65%70萬 | 204.54%4,653.3萬 | 49.02%1,534.9萬 | 6,513.03%2,263.8萬 |
除稅後利潤 | 3.39%1.98億 | 137.11%1.48億 | -37.13%2,956.2萬 | -118.02%-1,778.7萬 | 331.44%3,838萬 | 116.56%1.92億 | 17.75%6,235.8萬 | 186.70%4,702.4萬 | 549.54%9,872.4萬 | -527.18%-1,658.3萬 |
持續經營利潤 | 3.39%1.98億 | 137.11%1.48億 | -37.13%2,956.2萬 | -118.02%-1,778.8萬 | 331.43%3,838.1萬 | 116.56%1.92億 | 17.75%6,235.9萬 | 186.69%4,702.3萬 | 549.56%9,872.6萬 | -527.20%-1,658.4萬 |
歸屬于少數股東的淨利潤 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
歸屬於母公司的淨利潤 | 3.39%1.98億 | 137.11%1.48億 | -37.13%2,956.2萬 | -118.02%-1,778.7萬 | 331.44%3,838萬 | 116.56%1.92億 | 17.75%6,235.8萬 | 186.70%4,702.4萬 | 549.54%9,872.4萬 | -527.18%-1,658.3萬 |
優先股派息 | ||||||||||
其他優先股派息 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
歸屬于普通股股東的淨利潤 | 3.39%1.98億 | 137.11%1.48億 | -37.13%2,956.2萬 | -118.02%-1,778.7萬 | 331.44%3,838萬 | 116.56%1.92億 | 17.75%6,235.8萬 | 186.70%4,702.4萬 | 549.54%9,872.4萬 | -527.18%-1,658.3萬 |
總派息金額 | ||||||||||
基本每股收益 | 2.83%238.08 | 135.41%177.45 | -37.15%35.73 | -118.01%-21.5 | 331.42%46.4 | 117.32%231.53 | 18.08%75.38 | 187.27%56.85 | 552.90%119.35 | -533.05%-20.05 |
稀釋每股收益 | 2.86%231.77 | 135.50%172.76 | -37.14%34.78 | -118.01%-21.5 | 325.24%45.16 | 117.29%225.33 | 18.06%73.36 | 187.28%55.33 | 570.87%119.3472 | -544.57%-20.05 |
每股派息 | 0.00%25 | 0.00%25 | 0 | 0 | 0 | 66.67%25 | 66.67%25 | 0 | 0 | 0 |
貨幣單位 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 | 日元 |
會計準則 | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |